FDA warning letter · Drugs

Mobeen Mazhar, M.D.

Issued · Posted by FDA

Selected passages from the FDA letter

Quoted FDA text from the published dataset. These selected excerpts are not the complete letter.

Passage 1

You failed to ensure that the investigation was conducted according to the investigational plan [21 CFR 312.60].

Passage 2

You failed to obtain informed consent in accordance with the provisions of 21 CFR part 50 [21 CFR 312.60 and 21 CFR 50.20].

Passage 3

You failed to obtain legally effective informed consent for Subject **(b)(6)**, who was enrolled in Protocol **(b)(4)**. Specifically, study-related screening procedures and the start of the placebo run-in period were performed before you obtained this subject’s written informed consent on the screening/main study informed consent form.

Citations in the original letter

As cited in this historical letter, not a statement of current regulatory requirements.

  • 21 CFR 312.60
  • 21 CFR 312
  • 21 CFR 50
  • 21 CFR 50.20
  • 21 CFR 50.23
  • 21 CFR 50.24